Press Release
03 Feb, 2021
97
The subscription price of HK$14.45 per share represents an 8.32% premium to the average closing price of the five trading days immediately preceding the date of the Subscription Agreements (not including 2 February 2021).
3303
31 Dec, 2020
73
InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company, announced today the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its Bruton’s tyrosine kinase (BTK) inhibitor orelabrutinib for treatment of mantle cell lymphoma (MCL).
2372
27 Dec, 2020
142
InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company, announced today that its BTK inhibitor orelabrutinib received approval from the China National Medical Products Administration (NMPA) in two indications: the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (CLL) /small lymphocytic lymphoma (SLL), and the treatment of patients with relapsed/refractory mantle cell lymphoma (MCL). Both new drug applications (NDAs) were previously granted priority review by the Center for Drug Evaluation (CDE) of the NMPA.
2351
08 Dec, 2020
83
InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company, announced today three presentations of the most recent clinical data with orelabrutinib, its BTK inhibitor, at the 62nd American Society of Hematology (ASH) Annual Meeting.
2334
09 Nov, 2020
69
Beijing, Nov. 9, 2020——InnoCare Pharma (HKEX: 09969), a clinical-stage biopharmaceutical company, announced today that the company executives will attend a series of investor conferences to share company’s latest development in November.
2307